A Phase 3 interventional study of lenalidomide and Placebo in Lymphoma, Large B-Cell, Diffuse, sponsored by Celgene. Completed at 158 sites in 21 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-06-22.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 71 studies testing lenalidomide in Lymphoma, Large B-Cell, Diffuse — 14 open to participants now, 29 under way, 4 of them phase 3. Lenalidomide · Lymphoma, Large B-Cell, Diffuse.
Among the 71 studies testing lenalidomide in Lymphoma, Large B-Cell, Diffuse, this one is the 3rd largest by enrollment of the 70 interventional ones that give a count, is one of 3 that started in 2015, is one of 7 in phase 3, and was the 25th registered.
1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.
Browse Lymphoma, Large B-Cell, Diffuse studies →14 of the 71 studies testing lenalidomide in Lymphoma, Large B-Cell, Diffuse are open now, in 4 countries. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea · Sites in Spain
Ages 18+
Ruijin Hospital · Sites in China
Ages 18–75
Ruijin Hospital · Sites in China
Ages 70+
National Cancer Institute (NCI) · Sites in United States
Ages 18+
By country, each count listing its studies:
Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
71 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 30 · Phase 2 50 · Phase 3 8
First in 2002; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 570 is above the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.
Median enrollment 55 across the 70 interventional studies. Of the 31 that completed or were terminated, 15 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 71 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
22 studies in Lymphoma, Large B-Cell, Diffuse by Bristol-Myers Squibb: none open now, 1 under way, none of them phase 3. Of 20 finished, 11 (55%) have results posted.
Among the 22 studies in Lymphoma, Large B-Cell, Diffuse by Bristol-Myers Squibb, this one has the largest enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2015, is the only one in phase 3, and was the 8th registered.
Bristol-Myers Squibb’s Lymphoma, Large B-Cell, Diffuse studies by the year they started, since 2007.
4 of the studies testing lenalidomide in Lymphoma, Large B-Cell, Diffuse that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04978584M.D. Anderson Cancer CenterRituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study | 2027-01-16 |
| NCT06015880National Cancer Institute (NCI)Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | 2027-06-30 |
| NCT04609046National Cancer Institute (NCI)Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma | 2027-08-01 |
| NCT03223610National Cancer Institute (NCI)Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma | 2027-08-12 |
Add all 4 to your calendar (.ics) → With an account.
Among the 71 studies testing lenalidomide in Lymphoma, Large B-Cell, Diffuse, from their registry updates:
Among Bristol-Myers Squibb’s 22 in Lymphoma, Large B-Cell, Diffuse:
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy and safety of lenalidomide, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R2-CHOP) chemotherapy versus placebo, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (placebo-R-CHOP) chemotherapy in patients who have previously untreated ABC type DLBCL.
This research study is for patients with newly diagnosed Diffuse Large B-cell Lymphoma (DLBCL) of the activated B-cell (ABC) type who have not yet been treated. DLBCL is a cancer of a type of blood cell called B-lymphocytes. B lymphocytes are part of the body's immune system. There are different types of DLBCL. About a third of newly diagnosed DLBCL cancers are the ABC type. It has been observed that treatment does not work as well for patients with the ABC type compared to patients with other DLBCL types who receive standard treatment. However, at this time both ABC type and other DLBCL type patients receive the same standard treatments.
Patients with DLBCL who are otherwise healthy are usually treated first with the chemotherapy drug combination called R-CHOP. The drugs in this combination are "R" for rituximab, "C" for cyclophosphamide, "H" for doxorubicin which has a chemical name of hydroxydaunomycin, "O" for vincristine which has a trade name of oncovin, and "P" for prednisone. Depending on the local practice where you are treated, R-CHOP may be given for 6 or 8 cycles. A cycle could lasts for 14 or 21 days. The R-CHOP drug combination is approved for the treatment of DLBCL of all types, including ABC type. R-CHOP is standard care.
This study will test the standard R-CHOP21 against R-CHOP21 plus lenalidomide. The purpose is to see whether adding lenalidomide works better and is as safe as R-CHOP by itself. This study is only for patients with ABC type DLBCL who have not yet been treated. Lenalidomide is not approved for use in DLBCL. Its use in this disease is experimental. In this study, the experimental treatment is lenalidomide + R-CHOP21 x 6.
This study will use a gene expression profile (GEP) test to see if a patient has the ABC type. The results of this GEP test affect whether you may be treated on this study. Because the performance of this test has not been proven, it is for investigational use only, and is still under development. This means the GEP test is an experimental test.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lenalidomide plus R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)
Drug: lenalidomide · Drug: Rituximab · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: prednisone · Drug: vincristine
Placebo plus R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)
Drug: Placebo · Drug: Rituximab · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: prednisone · Drug: vincristine
Kaplan-Meier Estimate of Progression Free Survival (PFS)
Progression free survival was defined as the time (months) from the date of randomization to the date of disease progression or death (any cause), whichever occurred earlier and was assessed by the Independent Response Adjudication Committee (IRAC). Relapse from complete response (CR) was considered as disease progression throughout the study. Disease progression was determined based on the Revised Response Criteria for Malignant Lymphoma. The PFS analysis was based on the censoring rules using the Food and Drug Administration (FDA) Guidance. Participants who did not experience disease progression and who did not die before the clinical data cutoff date were censored at the date of last adequate response assessment.
Time frame: From the date of randomization up to the data cut off date of 15 March 2019; median follow-up of 24.5 months
Kaplan-Meier (K-M) Estimate of Event Free Survival (EFS)
EFS was defined as the time (months) from randomization until occurrence of one of the following events, whichever occurred first: • Disease progression • Initiation of subsequent systemic anti-lymphoma therapy • Death due to any cause The assessment of EFS was conducted by the IRAC using the International Working Group (IWG) criteria for NHL. Pre-specified optional therapies such as the extra 2 doses of single agent rituximab after Cycle 6 or consolidation radiotherapy did not count as an EFS event (initiation of subsequent systemic anti-lymphoma therapy) if the decision to treat and the location to be treated was determined prior to randomization. Participants who did not experience any of the events defined in the categories above before the clinical data cutoff date were censored at date last known alive.
Time frame: From the date of randomization up to the data cut off date of 15 March 2019; median follow-up was 24.5 months
K-M Estimate of Overall Survival (OS)
Overall survival was assessed by the Independent Response Adjudication Committee (IRAC) and defined as time from randomization until death due to any cause. Participants who withdrew consent were censored at the time of withdrawal. Participants who were still alive before the clinical data cutoff date and participants who were lost to follow-up were censored at date last known alive.
Time frame: From randomization until death due to any cause (up to approximately 86 months)
Percentage of Participants Who Achieved a Complete Response (CR)
The percentage of participants who achieved a CR after initiation of the study treatment and prior to initiation of subsequent systemic antilymphoma therapy as assessed by the IRAC. A CR = complete metabolic response; target nodes/nodal masses regressed on computed tomography to (≤ 1.5 cm in their greatest transverse diameter for nodes \> 1.5 cm prior to therapy. Regressed to normal size by imaging, and absence of nodules related to lymphoma. If bone marrow was involved prior to therapy, no evidence of fluorodeoxyglucose avid disease in marrow per International Working Group (IWG) 2014 for Non-Hodgkin's Lymphoma (NHL). Participants who did not have any adequate response assessments during this period were not considered as responders.
Time frame: From randomization date up to the data cut off date of 15 March 2019; median follow-up was 24.5 months
Percentage of Participants Who Achieved an Objective Response
An objective response = percentage of participants who achieved a complete response or partial response after initiation of the treatment and prior to initiation of subsequent systemic anti-lymphoma therapy. A CR = complete metabolic response; Target nodes/nodal masses regressed on computed tomography to (≤ 1.5 cm in their greatest transverse diameter for nodes \> 1.5 cm prior to therapy. Regressed to normal size by imaging, and absence of nodules related to lymphoma. If bone marrow was involved prior to therapy, no evidence of fluorodeoxyglucose avid disease in marrow. PR = ≥ 50% decrease in sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses. No increase in other nodes, liver, or spleen. Splenic nodules regressed by ≥ 50% in their SPD or for single nodules, in the greatest transverse diameter; no new lesions. Participants who did not have any adequate response assessments during this period were not considered as responders.
Time frame: From randomization date up to the data cut off date of 15 March 2019; median total treatment duration was 18.10 weeks for both treatment arms; range = 1.6 to 29.0 weeks for R2-CHOP arm and 0.3 to 22.9 weeks for placebo-R-CHOP arm
K-M Estimate of Duration of Complete Response
Duration of complete response was calculated for complete responders only and was defined as the time from documented initial complete response prior to initiation of subsequent systemic antilymphoma therapy until documented disease progression or death, whichever occurred earlier. Participants who had not progressed or died at the time of the analysis were censored at the date of last response assessment demonstrating no disease progression. Participants who changed treatment without evidence of disease progression were censored at the last assessment showing no progression prior to treatment change.
Time frame: From randomization date up to the data cut off date of 15 March 2019; median follow-up was 24.5 months.
K-M Estimate of Time to Next Lymphoma Therapy (TTNLT)
Time to next lymphoma therapy was defined as the time from randomization to the time of treatment change for the next lymphoma treatment. Participants without treatment change were censored at date last known alive. Pre-specified optional therapies such as the extra 2 doses of single agent rituximab after Cycle 6 or consolidation radiotherapy did not count as treatment change for the next lymphoma therapy if the decision to treat and the location to be treated were determined prior to randomization.
Time frame: From randomization date up to the data cut off date of 15 March 2019; median follow-up was 24.5 months
Percentage of Participants Who Completed the Functional Assessment of Cancer Therapy Lymphoma (FACT-Lym) Questionnaire
The completion rate for FACT-Lym assessments was judged by looking at the number of completed FACT-Lym assessments at each time point. The FACT-Lym was considered completed if at least 1 calculable score was present. Completion rates were calculated as the number and percentage of participants out of the total number of patients in the ITT population and summarized by visit/cycle and treatment group. The FACT-Lym is a health related quality of life (HRQoL) questionnaire targeted to the management of chronic illness, predominantly within oncology and is considered an extension of the FACT-General questionnaire.
Time frame: Screening, Midcycle = after Cycle 3 but before Cycle 4, Cycle 6 Day 1 (C6D1), End of Treatment (C6,D21), and Follow-Up Period up to Week 34
Percentage of Participants Who Completed the Euroqol 5-Dimension 3-Level (EQ-5D-3L) Health Related Quality of Life (HR-QoL) Questionnaire
The completion rate for EQ-5D assessments was judged by looking at the number of completed assessments at each time point. Completion rates were calculated as the number and percentage of participants out of the total number of patients in the ITT population and summarized by visit/cycle and treatment group. The EQ-5D-3L is a generic, self-reported preference-based measure of health across five dimensions: mobility, self-care, pain, usual activities, and anxiety/depression. Each dimension has three levels of 'severity' corresponding to "no problems", "some problems" and "extreme problems". The instrument is scored using the United Kingdom (UK) index ranges from -0.594 - 1, where 0 equates to death and 1 equates to full health -0.594 is considered 'worse than death'.
Time frame: Screening, Midcycle = after Cycle 3 but before Cycle 4, Cycle 6 Day 1 (C6D1), End of Treatment (C6,D21), and Follow-Up Period up to Week 34
Mean Change From Baseline in the FACT-Lym Physical Well-Being Subscale
The FACT-Lym questionnaire is a validated instrument for assessing the impact of lymphoma on HRQL and contains 42 questions covering HRQL and common lymphoma symptoms and treatment side-effects. It begins with the Functional Assessment of Cancer Therapy - General (FACT-G), which contains 27 questions covering four core subscales: Physical Wellbeing (7 items), Social/Family Wellbeing (7), Emotional Wellbeing (6), and Functional Wellbeing (7). The FACT-Lym also includes an Additional Concerns subscale (15 questions) used to assess NHL-related symptoms and concerns. All questions are answered on a 5-point scale ranging from "not at all" (0) to "very much" (4). The physical well-being subscale ranges from 0 to 28, where higher scores reflect better HRQoL.
Time frame: Baseline and Midcycle = after Cycle 3 but before Cycle 4, Cycle 6 Day 1 (C6D1), End of Treatment (C6,D21), and Follow-Up Period up to Week 34
Mean Change From Baseline in the FACT-Lym Additional Concerns Subscale
The FACT-Lym questionnaire is a validated instrument for assessing the impact of lymphoma on HRQL and contains 42 questions covering HRQL and common lymphoma symptoms and treatment side-effects. It begins with the Functional Assessment of Cancer Therapy - General (FACT-G), which contains 27 questions covering four core subscales: Physical Wellbeing (7 items), Social/Family Wellbeing (7), Emotional Wellbeing (6), and Functional Wellbeing (7). The FACT-Lym also includes an Additional Concerns subscale (15 questions) used to assess NHL-related symptoms such as pain, itching, night sweats,trouble sleeping, fatigue and trouble concentrating and concerns regarding lumps and swelling, fevers, infections, weight, appetite, emotional stability and treatment. All questions are answered on a 5-point scale ranging from "not at all" (0) to "very much" (4). The Additional Concerns subscale ranges from 0 to 60, where higher scores reflect better HRQoL.
Time frame: Baseline and Midcycle = after Cycle 3 but before Cycle 4, Cycle 6 Day 1 (C6D1), End of Treatment (C6,D21), and Follow-Up Period up to Week 34
Mean Change From Baseline in the FACT-Lym Functional Well-Being Subscale
The FACT-Lym questionnaire is a validated instrument for assessing the impact of lymphoma on HRQL and contains 42 questions covering HRQL and common lymphoma symptoms and treatment side-effects. It begins with the Functional Assessment of Cancer Therapy - General (FACT-G), which contains 27 questions covering four core subscales: Physical Wellbeing (7 items), Social/Family Wellbeing (7), Emotional Wellbeing (6), and Functional Wellbeing (7). The FACT-Lym also includes an Additional Concerns subscale (15 questions) used to assess NHL-related symptoms and concerns. All questions are answered on a 5-point scale ranging from "not at all" (0) to "very much" (4). The functional well-being subscale ranges from 0 to 28, where higher scores reflect better HRQoL.
Time frame: Baseline and Midcycle = after Cycle 3 but before Cycle 4, Cycle 6 Day 1 (C6D1), End of Treatment (C6,D21), and Follow-Up Period up to Week 34
Mean Change From Baseline in the FACT-Lym Trial Outcome Index (TOI)
The FACT-Lym questionnaire is a validated instrument for assessing the impact of lymphoma on HRQL and contains 42 questions covering HRQL and common lymphoma symptoms and treatment side-effects. It begins with the Functional Assessment of Cancer Therapy - General (FACT-G), which contains 27 questions covering four core subscales: Physical Wellbeing (7 items), Social/Family Wellbeing (7), Emotional Wellbeing (6), and Functional Wellbeing (7). The FACT-Lym also includes an Additional Concerns subscale (15 questions) used to assess NHL-related symptoms and concerns. All questions are answered on a 5-point scale ranging from "not at all" (0) to "very much" (4). The FACT-Lym TOI is calculated by summing the Physical Well-being, Functional Well-being and Additional Concerns scores and has a range of 0 to 116. Higher scores reflect better HRQoL or fewer symptoms.
Time frame: Baseline and Midcycle = after Cycle 3 but before Cycle 4, Cycle 6 Day 1 (C6D1), End of Treatment (C6,D21), and Follow-Up Period up to Week 34
Mean Change From Baseline in the Euroqol 5-Dimension 3-Level (EQ-5D-3L) Index Score
The EQ-5D-3L is a generic, self-reported preference-based measure of health across five dimensions: mobility, self-care, pain, usual activities, and anxiety/depression. Each dimension has three levels of 'severity' corresponding to "no problems", "some problems" and "extreme problems". The instrument is scored as a single summary index using one of the available EQ-5D-3L value sets; in this study the UK scoring weights 9 were used. The UK index ranges from -0.594 to 1, where 0 equates to death and 1 equates to full health (-0.594 is considered 'worse than death').
Time frame: Baseline and Midcycle = after Cycle 3 but before Cycle 4, Cycle 6 Day 1 (C6D1), End of Treatment (C6,D21), and Follow-Up Period up to Week 34
Mean Change From Baseline in the EQ-5D-3L Visual Analogue Scale (VAS)
The EQ-5D-3L questionnaire includes a visual analogue scale which records the respondent's self-rated health on a vertical, 0-100 scale where 100 = "Best imaginable health state" and 0 = "Worst imaginable health state". Higher scores again indicate better HRQoL and positive change scores indicate that post screening values were higher than those observed at screening. The EQ-5D-3L is a generic, self-reported preference-based measure of health across five dimensions: mobility, self-care, pain, usual activities, and anxiety/depression. Each dimension has three levels of 'severity' corresponding to "no problems", "some problems" and "extreme problems".
Time frame: Baseline and Midcycle = after Cycle 3 but before Cycle 4, Cycle 6 Day 1 (C6D1), End of Treatment (C6,D21), and Follow-Up Period up to Week 34
| Milestone | Lenalidomide Plus R-CHOP (R2-CHOP) | Placebo Plus R-CHOP |
|---|---|---|
| Started | 285 | 285 |
| Completed | 284 | 283 |
| Not completed | 1 | 2 |
| Withdrew: Protocol violation | 0 | 2 |
| Withdrew: Participant withdrew consent | 1 | 0 |
| Milestone | Lenalidomide Plus R-CHOP (R2-CHOP) | Placebo Plus R-CHOP |
|---|---|---|
| Started | 283 | 284 |
| Completed | 211 | 240 |
| Not completed | 72 | 44 |
Progression free survival was defined as the time (months) from the date of randomization to the date of disease progression or death (any cause), whichever occurred earlier and was assessed by the Independent Response Adjudication Committee (IRAC). Relapse from complete response (CR) was considered as disease progression throughout the study. Disease progression was determined based on the Revised Response Criteria for Malignant Lymphoma. The PFS analysis was based on the censoring rules using the Food and Drug Administration (FDA) Guidance. Participants who did not experience disease progression and who did not die before the clinical data cutoff date were censored at the date of last adequate response assessment.
| months | Lenalidomide Plus R-CHOP (R2-CHOP) | Placebo Plus R-CHOP |
|---|---|---|
| Kaplan-Meier Estimate of Progression Free Survival (PFS) | NA (NA to NA) | NA (35.5 to NA) |
EFS was defined as the time (months) from randomization until occurrence of one of the following events, whichever occurred first: • Disease progression • Initiation of subsequent systemic anti-lymphoma therapy • Death due to any cause The assessment of EFS was conducted by the IRAC using the International Working Group (IWG) criteria for NHL. Pre-specified optional therapies such as the extra 2 doses of single agent rituximab after Cycle 6 or consolidation radiotherapy did not count as an EFS event (initiation of subsequent systemic anti-lymphoma therapy) if the decision to treat and the location to be treated was determined prior to randomization. Participants who did not experience any of the events defined in the categories above before the clinical data cutoff date were censored at date last known alive.
| Months | Lenalidomide Plus R-CHOP (R2-CHOP) | Placebo Plus R-CHOP |
|---|---|---|
| Kaplan-Meier (K-M) Estimate of Event Free Survival (EFS) | NA (NA to NA) | NA (31.3 to NA) |
Overall survival was assessed by the Independent Response Adjudication Committee (IRAC) and defined as time from randomization until death due to any cause. Participants who withdrew consent were censored at the time of withdrawal. Participants who were still alive before the clinical data cutoff date and participants who were lost to follow-up were censored at date last known alive.
| Months | Lenalidomide Plus R-CHOP (R2-CHOP) | Placebo Plus R-CHOP |
|---|---|---|
| K-M Estimate of Overall Survival (OS) | NA (NA to NA) | NA (NA to NA) |
The percentage of participants who achieved a CR after initiation of the study treatment and prior to initiation of subsequent systemic antilymphoma therapy as assessed by the IRAC. A CR = complete metabolic response; target nodes/nodal masses regressed on computed tomography to (≤ 1.5 cm in their greatest transverse diameter for nodes \> 1.5 cm prior to therapy. Regressed to normal size by imaging, and absence of nodules related to lymphoma. If bone marrow was involved prior to therapy, no evidence of fluorodeoxyglucose avid disease in marrow per International Working Group (IWG) 2014 for Non-Hodgkin's Lymphoma (NHL). Participants who did not have any adequate response assessments during this period were not considered as responders.
| Percentage of Participants | Lenalidomide Plus R-CHOP (R2-CHOP) | Placebo Plus R-CHOP |
|---|---|---|
| Percentage of Participants Who Achieved a Complete Response (CR) | 69.1 (63.4 to 74.4) | 64.9 (59.1 to 70.4) |
An objective response = percentage of participants who achieved a complete response or partial response after initiation of the treatment and prior to initiation of subsequent systemic anti-lymphoma therapy. A CR = complete metabolic response; Target nodes/nodal masses regressed on computed tomography to (≤ 1.5 cm in their greatest transverse diameter for nodes \> 1.5 cm prior to therapy. Regressed to normal size by imaging, and absence of nodules related to lymphoma. If bone marrow was involved prior to therapy, no evidence of fluorodeoxyglucose avid disease in marrow. PR = ≥ 50% decrease in sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses. No increase in other nodes, liver, or spleen. Splenic nodules regressed by ≥ 50% in their SPD or for single nodules, in the greatest transverse diameter; no new lesions. Participants who did not have any adequate response assessments during this period were not considered as responders.
| Percentage of Participants | Lenalidomide Plus R-CHOP (R2-CHOP) | Placebo Plus R-CHOP |
|---|---|---|
| Percentage of Participants Who Achieved an Objective Response | 90.9 (86.9 to 94.0) | 90.9 (86.9 to 94.0) |
Duration of complete response was calculated for complete responders only and was defined as the time from documented initial complete response prior to initiation of subsequent systemic antilymphoma therapy until documented disease progression or death, whichever occurred earlier. Participants who had not progressed or died at the time of the analysis were censored at the date of last response assessment demonstrating no disease progression. Participants who changed treatment without evidence of disease progression were censored at the last assessment showing no progression prior to treatment change.
| Months | Lenalidomide Plus R-CHOP (R2-CHOP) | Placebo Plus R-CHOP |
|---|---|---|
| K-M Estimate of Duration of Complete Response | NA (NA to NA) | NA (NA to NA) |
Time to next lymphoma therapy was defined as the time from randomization to the time of treatment change for the next lymphoma treatment. Participants without treatment change were censored at date last known alive. Pre-specified optional therapies such as the extra 2 doses of single agent rituximab after Cycle 6 or consolidation radiotherapy did not count as treatment change for the next lymphoma therapy if the decision to treat and the location to be treated were determined prior to randomization.
| Months | Lenalidomide Plus R-CHOP (R2-CHOP) | Placebo Plus R-CHOP |
|---|---|---|
| K-M Estimate of Time to Next Lymphoma Therapy (TTNLT) | NA (NA to NA) | NA (NA to NA) |
The completion rate for FACT-Lym assessments was judged by looking at the number of completed FACT-Lym assessments at each time point. The FACT-Lym was considered completed if at least 1 calculable score was present. Completion rates were calculated as the number and percentage of participants out of the total number of patients in the ITT population and summarized by visit/cycle and treatment group. The FACT-Lym is a health related quality of life (HRQoL) questionnaire targeted to the management of chronic illness, predominantly within oncology and is considered an extension of the FACT-General questionnaire.
| Percentage of Participants | Lenalidomide Plus R-CHOP (R2-CHOP) | Placebo Plus R-CHOP |
|---|---|---|
| Screening | 98.6 | 98.2 |
| Midcycle = After Cycle 3, but before Cycle 4 | 87.0 | 86.3 |
| End of Treatment (EoT) = 3-4 weeks after C6 | 76.1 | 79.6 |
| Follow-Up Period: Week 34 | 67.7 | 69.5 |
The completion rate for EQ-5D assessments was judged by looking at the number of completed assessments at each time point. Completion rates were calculated as the number and percentage of participants out of the total number of patients in the ITT population and summarized by visit/cycle and treatment group. The EQ-5D-3L is a generic, self-reported preference-based measure of health across five dimensions: mobility, self-care, pain, usual activities, and anxiety/depression. Each dimension has three levels of 'severity' corresponding to "no problems", "some problems" and "extreme problems". The instrument is scored using the United Kingdom (UK) index ranges from -0.594 - 1, where 0 equates to death and 1 equates to full health -0.594 is considered 'worse than death'.
| Percentage of Participants | Lenalidomide Plus R-CHOP (R2-CHOP) | Placebo Plus R-CHOP |
|---|---|---|
| Screening | 98.9 | 97.9 |
| Midcycle | 87.0 | 86.3 |
| End of Treatment (EoT) | 76.5 | 79.6 |
| Follow-Up Period: Week 34 | 68.1 | 69.1 |
The FACT-Lym questionnaire is a validated instrument for assessing the impact of lymphoma on HRQL and contains 42 questions covering HRQL and common lymphoma symptoms and treatment side-effects. It begins with the Functional Assessment of Cancer Therapy - General (FACT-G), which contains 27 questions covering four core subscales: Physical Wellbeing (7 items), Social/Family Wellbeing (7), Emotional Wellbeing (6), and Functional Wellbeing (7). The FACT-Lym also includes an Additional Concerns subscale (15 questions) used to assess NHL-related symptoms and concerns. All questions are answered on a 5-point scale ranging from "not at all" (0) to "very much" (4). The physical well-being subscale ranges from 0 to 28, where higher scores reflect better HRQoL.
| Units on a Scale | Lenalidomide Plus R-CHOP (R2-CHOP) | Placebo Plus R-CHOP |
|---|---|---|
| Midcycle | -0.7 ± 5.91 | 0.2 ± 5.40 |
| C6 D1 | -0.0 ± 6.35 | 0.9 ± 6.02 |
| EoT = 3-4 weeks after C6 | 1.5 ± 5.53 | 0.7 ± 5.72 |
| Follow-Up Period: Week 34 | 2.8 ± 5.24 | 2.6 ± 5.55 |
The FACT-Lym questionnaire is a validated instrument for assessing the impact of lymphoma on HRQL and contains 42 questions covering HRQL and common lymphoma symptoms and treatment side-effects. It begins with the Functional Assessment of Cancer Therapy - General (FACT-G), which contains 27 questions covering four core subscales: Physical Wellbeing (7 items), Social/Family Wellbeing (7), Emotional Wellbeing (6), and Functional Wellbeing (7). The FACT-Lym also includes an Additional Concerns subscale (15 questions) used to assess NHL-related symptoms such as pain, itching, night sweats,trouble sleeping, fatigue and trouble concentrating and concerns regarding lumps and swelling, fevers, infections, weight, appetite, emotional stability and treatment. All questions are answered on a 5-point scale ranging from "not at all" (0) to "very much" (4). The Additional Concerns subscale ranges from 0 to 60, where higher scores reflect better HRQoL.
| Units on a Scale | Lenalidomide Plus R-CHOP (R2-CHOP) | Placebo Plus R-CHOP |
|---|---|---|
| Midcycle | 3.8 ± 10.33 | 4.1 ± 8.88 |
| C6 D1 | 5.8 ± 11.11 | 5.2 ± 9.40 |
| EoT = 3-4 weeks after C6 | 6.6 ± 10.11 | 4.5 ± 9.62 |
| Follow-Up Period: Week 34 | 8.3 ± 10.61 | 6.5 ± 9.20 |
The FACT-Lym questionnaire is a validated instrument for assessing the impact of lymphoma on HRQL and contains 42 questions covering HRQL and common lymphoma symptoms and treatment side-effects. It begins with the Functional Assessment of Cancer Therapy - General (FACT-G), which contains 27 questions covering four core subscales: Physical Wellbeing (7 items), Social/Family Wellbeing (7), Emotional Wellbeing (6), and Functional Wellbeing (7). The FACT-Lym also includes an Additional Concerns subscale (15 questions) used to assess NHL-related symptoms and concerns. All questions are answered on a 5-point scale ranging from "not at all" (0) to "very much" (4). The functional well-being subscale ranges from 0 to 28, where higher scores reflect better HRQoL.
| Units on a Scale | Lenalidomide Plus R-CHOP (R2-CHOP) | Placebo Plus R-CHOP |
|---|---|---|
| Midcycle | -0.5 ± 6.12 | 0.5 ± 5.84 |
| C6 D1 | 0.0 ± 6.24 | 1.4 ± 5.63 |
| EoT = 3-4 weeks after C6 | 1.0 ± 6.53 | 0.7 ± 6.71 |
| Follow-Up Period: Week 34 | 2.3 ± 6.65 | 3.1 ± 6.17 |
The FACT-Lym questionnaire is a validated instrument for assessing the impact of lymphoma on HRQL and contains 42 questions covering HRQL and common lymphoma symptoms and treatment side-effects. It begins with the Functional Assessment of Cancer Therapy - General (FACT-G), which contains 27 questions covering four core subscales: Physical Wellbeing (7 items), Social/Family Wellbeing (7), Emotional Wellbeing (6), and Functional Wellbeing (7). The FACT-Lym also includes an Additional Concerns subscale (15 questions) used to assess NHL-related symptoms and concerns. All questions are answered on a 5-point scale ranging from "not at all" (0) to "very much" (4). The FACT-Lym TOI is calculated by summing the Physical Well-being, Functional Well-being and Additional Concerns scores and has a range of 0 to 116. Higher scores reflect better HRQoL or fewer symptoms.
| Units on a Scale | Lenalidomide Plus R-CHOP (R2-CHOP) | Placebo Plus R-CHOP |
|---|---|---|
| Midcycle | 2.6 ± 18.26 | 4.6 ± 16.49 |
| C6 D1 | 5.9 ± 19.85 | 7.5 ± 17.40 |
| EoT = 3-4 weeks after C6 | 9.1 ± 18.51 | 5.8 ± 18.64 |
| Follow-Up Period: Week 34 | 13.5 ± 18.74 | 12.2 ± 17.97 |
The EQ-5D-3L is a generic, self-reported preference-based measure of health across five dimensions: mobility, self-care, pain, usual activities, and anxiety/depression. Each dimension has three levels of 'severity' corresponding to "no problems", "some problems" and "extreme problems". The instrument is scored as a single summary index using one of the available EQ-5D-3L value sets; in this study the UK scoring weights 9 were used. The UK index ranges from -0.594 to 1, where 0 equates to death and 1 equates to full health (-0.594 is considered 'worse than death').
| Units on a Scale | Lenalidomide Plus R-CHOP (R2-CHOP) | Placebo Plus R-CHOP |
|---|---|---|
| Midcycle | 0.08 ± 0.308 | 0.08 ± 0.281 |
| C6 D1 | 0.10 ± 0.325 | 0.14 ± 0.330 |
| EoT = 3-4 weeks after C6 | 0.10 ± 0.309 | 0.06 ± 0.319 |
| Follow-Up Period: Week 34 | 0.15 ± 0.293 | 0.09 ± 0.311 |
The EQ-5D-3L questionnaire includes a visual analogue scale which records the respondent's self-rated health on a vertical, 0-100 scale where 100 = "Best imaginable health state" and 0 = "Worst imaginable health state". Higher scores again indicate better HRQoL and positive change scores indicate that post screening values were higher than those observed at screening. The EQ-5D-3L is a generic, self-reported preference-based measure of health across five dimensions: mobility, self-care, pain, usual activities, and anxiety/depression. Each dimension has three levels of 'severity' corresponding to "no problems", "some problems" and "extreme problems".
| Units on a Scale | Lenalidomide Plus R-CHOP (R2-CHOP) | Placebo Plus R-CHOP |
|---|---|---|
| Midcycle | 4.0 ± 20.5 | 3.0 ± 18.2 |
| C6 D1 | 6.0 ± 23.5 | 9.0 ± 24.5 |
| EoT = 3-4 weeks after C6 | 8.0 ± 18.7 | 6.0 ± 21.5 |
| Follow-Up Period: Week 34 | 12.0 ± 20.2 | 9 ± 21.4 |
Collected over Participants were assessed for All-Cause Mortality from the date of their randomization until study completion (assessed up to approximately 86 months). SAEs and Other AEs were monitored from the participant's first dose of study treatment up to 28 days after their last dose of LEN/PBO or any component of R-CHOP including the optional 2 additional doses of rituximab; measured up to approximately 33 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lenalidomide Plus R-CHOP (R2-CHOP) | 85/285 (29.8%) | 104/283 (36.7%) | 272/283 (96.1%) |
| Placebo Plus R-CHOP | 88/285 (30.9%) | 88/284 (31%) | 270/284 (95.1%) |
| Event | Lenalidomide Plus R-CHOP (R2-CHOP) | Placebo Plus R-CHOP |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 31/283 | 14/284 |
| NeutropeniaBlood and lymphatic system disorders | 19/283 | 13/284 |
| ThrombocytopeniaBlood and lymphatic system disorders | 16/283 | 1/284 |
| PneumoniaInfections and infestations | 15/283 | 9/284 |
| PyrexiaGeneral disorders | 7/283 | 9/284 |
| AnaemiaBlood and lymphatic system disorders | 6/283 | 6/284 |
| DiarrhoeaGastrointestinal disorders | 6/283 | 4/284 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 5/283 | 3/284 |
| Abdominal painGastrointestinal disorders | 4/283 | 0/284 |
| Atrial fibrillationCardiac disorders | 2/283 | 4/284 |
| Event | Lenalidomide Plus R-CHOP (R2-CHOP) | Placebo Plus R-CHOP |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 183/283 | 150/284 |
| AnaemiaBlood and lymphatic system disorders | 127/283 | 95/284 |
| ConstipationGastrointestinal disorders | 92/283 | 81/284 |
| ThrombocytopeniaBlood and lymphatic system disorders | 68/283 | 55/284 |
| NauseaGastrointestinal disorders | 64/283 | 66/284 |
| PyrexiaGeneral disorders | 52/283 | 40/284 |
| Peripheral sensory neuropathyNervous system disorders | 51/283 | 51/284 |
| LeukopeniaBlood and lymphatic system disorders | 50/283 | 50/284 |
| FatigueGeneral disorders | 40/283 | 50/284 |
| DiarrhoeaGastrointestinal disorders | 49/283 | 40/284 |
The Intent-to-treat (ITT) population was defined as all participants who were randomized into the trial, regardless of whether they received study treatment or not.
| Age, Continuous(Years) | Lenalidomide Plus R-CHOP (R2-CHOP) | Placebo Plus R-CHOP | Total |
|---|---|---|---|
| Mean | 62.5 ± 11.72 | 63.9 ± 9.35 | 63.2 ± 10.62 |
| Age, Customized(Participants) | Lenalidomide Plus R-CHOP (R2-CHOP) | Placebo Plus R-CHOP | Total |
|---|---|---|---|
| < 65 | 138 | 137 | 275 |
| ≥ 65 | 147 | 148 | 295 |
| Sex: Female, Male(Participants) | Lenalidomide Plus R-CHOP (R2-CHOP) | Placebo Plus R-CHOP | Total |
|---|---|---|---|
| Female | 121 | 142 | 263 |
| Male | 164 | 143 | 307 |
| Ethnicity (NIH/OMB)(Participants) | Lenalidomide Plus R-CHOP (R2-CHOP) | Placebo Plus R-CHOP | Total |
|---|---|---|---|
| Hispanic or Latino | 14 | 17 | 31 |
| Not Hispanic or Latino | 270 | 267 | 537 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Race/Ethnicity, Customized(Participants) | Lenalidomide Plus R-CHOP (R2-CHOP) | Placebo Plus R-CHOP | Total |
|---|---|---|---|
| White | 173 | 183 | 356 |
| Asian | 101 | 89 | 190 |
| Black or African American | 2 | 3 | 5 |
| Other | 3 | 2 | 5 |
| Not Collected or Reported | 6 | 8 | 14 |
| Body Surface Area (BSA)(m^2) | Lenalidomide Plus R-CHOP (R2-CHOP) | Placebo Plus R-CHOP | Total |
|---|---|---|---|
| Mean | 1.780 ± 0.2167 | 1.775 ± 0.2101 | 1.777 ± 0.2132 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants) | Lenalidomide Plus R-CHOP (R2-CHOP) | Placebo Plus R-CHOP | Total |
|---|---|---|---|
| 0 = Fully Active | 129 | 111 | 240 |
| 1 = Restrictive but ambulatory | 104 | 118 | 222 |
| 2 = Ambulatory but unable to work | 52 | 56 | 108 |
| Creatinine Clearance(mL/min) | Lenalidomide Plus R-CHOP (R2-CHOP) | Placebo Plus R-CHOP | Total |
|---|---|---|---|
| Mean | 92.08 ± 35.576 | 90.19 ± 31.040 | 91.14 ± 33.373 |
3 further baseline measures are reported on the registry.
Showing the first 100 of 158 sites across 21 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2015 to primary completion in Mar 2019, 48 months.
Results were first posted in Mar 2020, 1 year after primary completion.
Of 37 industry-sponsored phase 3 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 82. This study's 48 months is close to that.
Counting every sponsor, half of 73 studies reached it within 57 months; a quarter within 39 and three quarters within 99.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lenalidomide
Lymphoma, Large B-Cell, Diffuse →